Premium
Resiniferatoxin for treatment of lifelong premature ejaculation: A preliminary study
Author(s) -
Shi Bentao,
Li Xuesong,
Chen Jing,
Su Boxing,
Li Xianxin,
Yang Shangqi,
Guan Zhichen,
Wang Run
Publication year - 2014
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12471
Subject(s) - resiniferatoxin , premature ejaculation , medicine , ejaculation , placebo , sexual intercourse , urology , sexual function , anesthesia , surgery , psychology , population , receptor , alternative medicine , environmental health , pathology , transient receptor potential channel , trpv1 , psychoanalysis
Objectives To evaluate the efficacy of resiniferatoxin in the treatment of patients with lifelong premature ejaculation. Methods A total of 41 outpatients (mean age 26.14 ± 4 years) with premature ejaculation completed the present study. They were randomly separated into the resiniferatoxin group and the placebo group. The resiniferatoxin group included 11 patients with redundant prepuce and 10 patients without redundant prepuce, whereas the placebo group contained 10 patients with redundant prepuce and 10 patients without. For the treatment, the glans were respectively soaked in 30 mL of resiniferatoxin with a concentration of 100 nmol/L or 10% alcohol solution for 30 min before sexual intercourse. Clinical efficacy was assessed by using the C hinese Index of Sexual Function for Premature Ejaculation‐5 and the intravaginal ejaculation latency time before or 4 weeks after the treatment. The side‐effects were also evaluated. Results In the resiniferatoxin group, the effective rate of patients with redundant prepuce was 63.6%, and both the intravaginal ejaculation latency time and C hinese Index of Sexual Function for Premature Ejaculation‐5 significantly increased ( P < 0.05). However, the effective rate of patients without redundant prepuce was 20%, and there were no significant changes of their intravaginal ejaculation latency time and C hinese Index of Sexual Function for Premature Ejaculation‐5 before and after the resiniferatoxin treatment ( P > 0.05). The total effective rate of patients treated with resiniferatoxin was 42.9%. In the placebo group, the effective rate of patients with or without redundant prepuce was 20% and 10%, respectively. The total effective rate of patients treated with placebo was 15%, and there were no significant changes of their intravaginal ejaculation latency time and C hinese Index of Sexual Function for Premature Ejaculation‐5 before and after the placebo treatment ( P > 0.05). The side‐effects included a slight burning sensation for the glans penis and dysuria. Conclusions These preliminary results show that resiniferatoxin might be suitable for treating patients with lifelong premature ejaculation and particularly those with redundant prepuce.